Wells Fargo just kicked off coverage on Arcellx (ACLX), zeroing in on its experimental CAR T therapy for multiple myeloma as a potential future treatment backbone and putting the company more firmly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback